ARQT
Heron Patrick J, ARQT's Director, spent $34.6K of their own money on 2,646 shares at $13, growing their stake 11%.
+$34.6K
2,646 sh @ $13
ARQT
Arcutis Biotherapeutics, Inc.
SEC CIK 1787306
$24.38
−6.5% · 90 days
90-day buys
$0
0 open-market
90-day sells
$0
0 open-market
Net insider flow
+$0
Net buying
Filings shown
14
Most recent
Advertisement
At a glance
Insiders at ARQT have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.
Largest recent trade: Frazier Life Sciences Viii, L.p., ARQT's 10% owner, spent $8.5M of their own money on 500,000 shares at $17, growing their stake 5%.
Most active filer: Heron Patrick J, with 10 transactions among the recent filings shown.
Insider transaction history
Form 4 filings for ARQT, newest firstARQT
Heron Patrick J, ARQT's Director, spent $5.1K of their own money on 378 shares at $13, growing their stake 2%.
+$5.1K
378 sh @ $13
ARQT
Heron Patrick J, ARQT's Director, spent $25.2K of their own money on 1,890 shares at $13, growing their stake 8%.
+$25.2K
1,890 sh @ $13
ARQT
Heron Patrick J, ARQT's Director, spent $34.4K of their own money on 2,520 shares at $14, growing their stake 13%.
+$34.4K
2,520 sh @ $14
ARQT
Heron Patrick J, ARQT's Director, spent $34.4K of their own money on 2,520 shares at $14, growing their stake 14%.
+$34.4K
2,520 sh @ $14
Advertisement
ARQT
Heron Patrick J, ARQT's Director, spent $34.3K of their own money on 2,520 shares at $14, growing their stake 17%.
+$34.3K
2,520 sh @ $14
ARQT
Heron Patrick J, ARQT's Director, spent $86.7K of their own money on 6,300 shares at $14, growing their stake 73%.
+$86.7K
6,300 sh @ $14
ARQT
Heron Patrick J, ARQT's Director, spent $32.7K of their own money on 2,374 shares at $14, growing their stake 38%.
+$32.7K
2,374 sh @ $14
ARQT
Heron Patrick J, ARQT's Director, spent $85.7K of their own money on 6,300 shares at $14, opening a brand-new position.
+$85.7K
6,300 sh @ $14
ARQT
Heron Patrick J, ARQT's Director, spent $200K of their own money on 21,052 shares at $10.
+$200K
21,052 sh @ $10
ARQT
Frazier Life Sciences Viii, L.p., ARQT's 10% owner, spent $200K of their own money on 80,000 shares at $3, growing their stake 1%.
+$200K
80,000 sh @ $3
ARQT
Frazier Life Sciences Viii, L.p., ARQT's 10% owner, spent $5M of their own money on 250,000 shares at $20, growing their stake 3%.
+$5M
250,000 sh @ $20
ARQT
Bain Capital Life Sciences Investors, Llc, ARQT's 10% owner, spent $5M of their own money on 294,117 shares at $17, growing their stake 8%.
+$5M
294,117 sh @ $17
ARQT
Frazier Life Sciences Viii, L.p., ARQT's 10% owner, spent $8.5M of their own money on 500,000 shares at $17, growing their stake 5%.
+$8.5M
500,000 sh @ $17
Advertisement
About ARQT insider activity
This page tracks every recent Form 4 filed for Arcutis Biotherapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.
The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.
Frequently asked questions
How often is ARQT insider data updated?
Continuously. We read from SEC EDGAR, so new Form 4 filings for Arcutis Biotherapeutics, Inc. usually appear here within minutes of being accepted by the SEC.
What does "net insider flow" mean?
It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.
Why do some rows show grants or option exercises instead of buys?
Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.
Is this investment advice?
No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.